DOI: https://dx.doi.org/10.18203/issn.2454-5929.ijohns20222088
Published: 2022-08-25

Impact of HPV vaccination on number of surgical procedures required in recurrent respiratory papillomatosis and its potential use as an adjuvant

Mohammed Afeef Aslam, Yusuf Maududi

Abstract


People who suffer from recurrent respiratory papillomatosis have to undergo multiple surgical procedures for debulking resulting in complications such as reduced quality of voice. Data source was Pubmed articles. The objective of this study was to review the current literature on HPV vaccination and its impact on RRP and whether it may help reduce the number of surgical procedures required. Articles from year 2000 onwards were searched for on PubMed. Overall articles show significant increase in surgical intervals post HPV vaccination. HPV vaccination appears to be a safe adjuvant therapy in the management of recurrent respiratory papillomatosis.


Keywords


Recurrent respiratory papilloma, Human papilloma vaccine, Surgery

Full Text:

PDF

References


Rabah R, Lancaster WD, Thomas R, Gregoire L. Human papillomavirus-11-associated recurrent respiratory papillomatosis is more aggressive than human papillomavirus-6-associated disease. Pediatr Dev Pathol. 2001;4(1):68-72.

Kimberlin DW. Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis. Antiviral Res. 2004;63(3):141-51.

Fortes HR, Ranke FM, Escuissato DL, Neto CA, Zanetti G, Hochhegger B, et al. Recurrent respiratory papillomatosis: A state-of-the-art review. Respir Med. 2017;126:116-21.

Chadha NK, James A. Adjuvant antiviral therapy for recurrent respiratory papillomatosis. Cochrane Database Syst Rev. 2012;12(12):CD005053.

Derkay CS, Bluher AE. Update on Recurrent Respiratory Papillomatosis. Otolaryngol Clin North Am. 2019;52(4):669-79.

Lehto L, Aaltonen LM, Rihkanen H. Longstanding recurrent laryngeal papillomatosis: impact on voice quality. Eur Arch Otorhinolaryngol. 2007;264(7):777-82.

Ilmarinen T, Nissilä H, Rihkanen H, Roine RP, Pietarinen-Runtti P, Pitkäranta A, et al. Clinical features, health-related quality of life, and adult voice in juvenile-onset recurrent respiratory papillomatosis. Laryngoscope. 2011;121(4):846-51.

NHS. HPV vaccine overview, 2022. Available at: https://www.nhs.uk/conditions/vaccinations/hpvhuman-papillomavirus-vaccine/. Accessed on 20 July 2022.

Wangu Z, Hsu KK. Impact of HPV vaccination on anogenital warts and respiratory papillomatosis. Hum Vaccin Immunother. 2016;12(6):1357-62.

Boltežar I, Matičič M, Sereg-Bahar M, Gale N, Poljak M, Kocjan B, et al. Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol. 2014;271(12):3255-62.

Goon P, Scholtz LU, Sudhoff H. Recurrent respiratory papillomatosis (RRP)-time for a reckoning? Laryngoscope Investig Otolaryngol. 2017;2(4):184-6.

Dion GR, Teng S, Boyd LR, Northam A, Mason-Apps C, Vieira D, et al. Adjuvant Human Papillomavirus Vaccination for Secondary Prevention: A Systematic Review. JAMA Otolaryngol Head Neck Surg. 2017;143(6):614-22.

Rosenberg T, Philipsen BB, Mehlum CS, Dyrvig AK, Wehberg S, Chirilǎ M, et al. Therapeutic Use of the Human Papillomavirus Vaccine on Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-Analysis. J Infect Dis. 2019;219(7):1016-25.

Smahelova J, Hamsikova E, Ludvikova V, Vydrova J, Traboulsi J, Vencalek O, et al. Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis: A Nonrandomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2022;148(7):654-61.

Novakovic D, Cheng ATL, Zurynski Y, Booy R, Walker PJ, Berkowitz R, et al. A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program. J Infect Dis. 2018;217(2):208-12.

Markowitz LE, Gee J, Chesson H, Stokley S. Ten Years of Human Papillomavirus Vaccination in the United States. Acad Pediatr. 2018;18(2S):3-10.

Perkins RB, Legler A, Hanchate A. Trends in Male and Female Genital Warts Among Adolescents in a Safety-Net Health Care System 2004-2013: Correlation With Introduction of Female and Male Human Papillomavirus Vaccination. Sex Transm Dis. 2015;42(12):665-8.

Schaffer A, Brotherton J, Booy R. Do human papillomavirus vaccines have any role in newborns and the prevention of recurrent respiratory papillomatosis in children? J Paediatr Child Health. 2007;43(9):579-80.

Shah KV. A case for immunization of human papillomavirus (HPV) 6/11-infected pregnant women with the quadrivalent HPV vaccine to prevent juvenile-onset laryngeal papilloma. J Infect Dis. 2014;209(9):1307-9.

Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol. 2009;114(6):1179-88.

Healy CM. Vaccines in pregnant women and research initiatives. Clin Obstet Gynecol. 2012;55(2):474-86.